Acute kidney injury and acute kidney recovery following Transcatheter Aortic Valve Replacement.
Acute Kidney Injury
/ etiology
Aged
Aged, 80 and over
Cardiovascular Diseases
/ mortality
Creatinine
/ blood
Female
Follow-Up Studies
Glomerular Filtration Rate
Humans
Kaplan-Meier Estimate
Male
Proportional Hazards Models
Recovery of Function
/ physiology
Renal Insufficiency, Chronic
/ pathology
Transcatheter Aortic Valve Replacement
/ adverse effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
01
2021
accepted:
25
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Acute kidney injury (AKI) is associated with a dismal prognosis in Transcatheter Aortic Valve replacement (TAVR). Acute kidney recovery (AKR), a phenomenon reverse to AKI has recently been associated with better outcomes. Between November 2012 to May 2018, we explored consecutive patients referred to our Heart Valve Center for TAVR. AKI was defined according to the VARC-2 definition. Mirroring the VARC-2 definition of AKI, AKR was defined as a decrease in serum creatinine (≥50%) or ≥25% improvement in GFR up to 72 hours after TAVR. AKI and AKR were respectively observed in 8.3 and 15.7% of the 574 patients included. AKI and AKR patients were associated to more advanced kidney disease at baseline. At a median follow-up of 608 days (range 355-893), AKI and AKR patients experienced an increased cardiovascular mortality compared to unchanged renal function patients (14.6% and 17.8% respectively, vs. 8.1%, CI 95%, p<0.022). Chronic kidney disease, (HR: 3.9; 95% CI 1.7-9.2; p < 0.001) was the strongest independent factor associated with AKI similarly to baseline creatinine level (HR: 1; 95% CI 1 to 1.1 p < 0.001) for AKR. 72-hours post procedural AKR (HR: 2.26; 95% CI 1.14 to 4.88; p = 0.021) was the strongest independent predictor of CV mortality. Both AKR and AKI negatively impact long term clinical outcomes of patients undergoing TAVR.
Sections du résumé
BACKGROUND
Acute kidney injury (AKI) is associated with a dismal prognosis in Transcatheter Aortic Valve replacement (TAVR). Acute kidney recovery (AKR), a phenomenon reverse to AKI has recently been associated with better outcomes.
METHODS
Between November 2012 to May 2018, we explored consecutive patients referred to our Heart Valve Center for TAVR. AKI was defined according to the VARC-2 definition. Mirroring the VARC-2 definition of AKI, AKR was defined as a decrease in serum creatinine (≥50%) or ≥25% improvement in GFR up to 72 hours after TAVR.
RESULTS
AKI and AKR were respectively observed in 8.3 and 15.7% of the 574 patients included. AKI and AKR patients were associated to more advanced kidney disease at baseline. At a median follow-up of 608 days (range 355-893), AKI and AKR patients experienced an increased cardiovascular mortality compared to unchanged renal function patients (14.6% and 17.8% respectively, vs. 8.1%, CI 95%, p<0.022). Chronic kidney disease, (HR: 3.9; 95% CI 1.7-9.2; p < 0.001) was the strongest independent factor associated with AKI similarly to baseline creatinine level (HR: 1; 95% CI 1 to 1.1 p < 0.001) for AKR. 72-hours post procedural AKR (HR: 2.26; 95% CI 1.14 to 4.88; p = 0.021) was the strongest independent predictor of CV mortality.
CONCLUSIONS
Both AKR and AKI negatively impact long term clinical outcomes of patients undergoing TAVR.
Identifiants
pubmed: 34375346
doi: 10.1371/journal.pone.0255806
pii: PONE-D-21-00837
pmc: PMC8354447
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0255806Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Am Coll Cardiol. 2020 Sep 22;76(12):1422-1424
pubmed: 32943159
Can J Cardiol. 2021 Jun;37(6):904-912
pubmed: 33383167
Eur Heart J. 2017 Dec 1;38(45):3351-3358
pubmed: 29020232
Semin Nephrol. 2012 Jan;32(1):26-30
pubmed: 22365159
J Am Coll Cardiol. 2019 Jul 30;74(4):564-566
pubmed: 31345431
Circulation. 2000 Jul 11;102(2):203-10
pubmed: 10889132
JAMA Cardiol. 2016 Aug 1;1(5):584-92
pubmed: 27437665
J Clin Med. 2020 Mar 25;9(4):
pubmed: 32218228
Am J Cardiol. 2013 Jan 1;111(1):100-5
pubmed: 23040657
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23
pubmed: 23084102
J Am Heart Assoc. 2017 Jul 11;6(7):
pubmed: 28698259
Expert Rev Cardiovasc Ther. 2015 Mar;13(3):301-16
pubmed: 25592763
EuroIntervention. 2017 Apr 20;12(17):2067-2074
pubmed: 27890858
Am J Cardiol. 2018 Mar 1;121(5):634-641
pubmed: 29329828
Catheter Cardiovasc Interv. 2015 Sep;86(3):518-27
pubmed: 25641565
Am J Cardiol. 2018 May 15;121(10):1239-1245
pubmed: 29525062
Circulation. 2019 Apr 16;139(16):e840-e878
pubmed: 30852913
Nat Rev Nephrol. 2013 Feb;9(2):99-111
pubmed: 23247571